Nicotine Dependence Clinical Trial
Official title:
Brain Substrates of Extinction Based Treatment for Nicotine Dependence
The purpose of this study is to test two quit smoking therapies and to study brain function
while each therapy is being used. You will be randomly assigned (like flipping a coin) to
one of the two groups. The first therapy is Extinction-Based therapy (EBT). If you are in
this group, you will switch to smoking denicotinized cigarettes while wearing a 21 mg/d
nicotine patch for one month prior to your quit date. The second therapy is a standard
Nicotine Replacement therapy (NRT). If you are in this group, you will smoke your usual
brand of cigarettes up to the quit date. Following the quit date, both groups will undergo
standard nicotine replacement therapy (21 mg/d for 6 weeks; 14 mg/d for 2 weeks, 7 mg/d for
2 weeks).
In addition to the above, we will recruit a sample of former smokers who are now regular
users of e-cigarettes. This group [ECIG] will undergo the same screening and baseline
assessments as the EBT and NRT groups up to the completion of fMRI1.
If you agree to be in this study, you will be asked to sign the consent form prior to any
tests or procedures. You will be asked to come to the laboratory for a screening session.
The screening session will take approximately 1.5 hours to complete, including all
questionnaires, physical and sample collection. Pregnant or nursing mothers will not be
allowed to participate in this study. If you test positive for illegal drug use, you will
not be allowed to participate in this study. Depending on the results of the screening
procedures you may not be eligible for the study. If you do not have any medical conditions
that would make your participation risky, and you feel comfortable participating in the
study, you will be given instructions regarding the rest of the study sessions and be asked
to return.
Smoker participants who complete the screening visit (described above) and meet all study
requirements will then complete 8 lab visits, 1 fMRI training session, 3 fMRI sessions, and
2 follow-up visits. ECIG participants who complete the screening visit and meet all study
requirements will complete 1 fMRI training session and 1 fMRI session.
First you will be randomly assigned (like drawing out of a hat) to a study group, either the
EBT or NRT group. In the extinction-based therapy (EBT) group, participants will switch to
smoking denicotinized cigarettes while wearing a 21 mg/d nicotine patch for one month prior
to their quit date; meanwhile, smokers assigned to the nicotine replacement therapy (NRT)
group will smoke their usual brand of cigarettes up to the quit date. Following the quit
date, both groups will undergo standard nicotine replacement therapy (21 mg/d for 6 weeks;
14 mg/d for 2 weeks, 7 mg/d for 2 weeks).
Eight lab visits (V1 - V8) will be conducted during the 16 weeks following enrollment in the
study. These visits will be largely identical, except that instructions and reminders to you
about upcoming events will vary from session to session. At each lab visit the following
will be collected: vitals (heart rate, blood pressure and weight); breath CO (Carbon
Monoxide) and saliva samples for testing smoking and nicotine levels; and measures of
smoking withdrawal and mood. You will be given daily diaries to record your smoking behavior
and study medication. You will be given instructions on how and when to use all study
materials. Advice on quitting and minimal support will be provided as requested at these
visits. Each lab visit will require 20-30 minutes of your time.
Directly following V1 you will undergo a training session, during which you will be
familiarized with all aspects of the fMRI sessions including tasks and equipment. You will
be situated in a scanner simulator, which simulates the sounds and equipment used in the
fMRI scanner.
One task will require you to view pictures of people smoking and people doing everyday
activities. After the task, you will be quizzed on the pictures you saw. During another
task, you will be presented with a stream of gray, yellow, or blue colored circles and
instructed to press a button every time you see a "Go" trial while inhibiting a response
(not pressing the button) when you are presented with a "No-Go" trial. The training session
will require 1 hour of participant time.
fMRI Sessions:
You will be asked to complete three fMRI scanning sessions: a baseline scan (fMRI-1); a scan
4 weeks after you start treatment (fMRI-2); and a final scan 24 hours after your quit date
(fMRI-3). The first 20 minutes of each scanning session will follow the same protocol as a
lab visit. Following this, for fMRI-1 and fMRI-2 you will be asked to smoke a cigarette
(usual brand or denicotinized depending on session and group). No cigarette will be smoked
prior to fMRI-3. After smoking your cigarette you will sit in a quiet room and read
magazines for 30 minutes. Following the 30 min rest period, you will be escorted to the fMRI
suite at Duke University Medical Center. Once inside, you will complete questionnaires
regarding your current mood and withdrawal symptoms. We will take a CO and saliva sample at
the beginning of each scan. If you are wearing a nicotine replacement patch, you will remove
it before entering the scanner. Then you will be given specific instructions regarding data
collection procedures and be placed in the scanner. During the scanning you will perform
each of the tasks, and lie still while we take pictures of your brain. After being removed
from the scanner, you will complete post-session withdrawal and mood questionnaires and
replace the removed patch. End-of-session instructions will then be provided:
- At the end of fMRI-1, ECIG participants will be released from the study. Smoker
participants will be randomly assigned to either the EBT or NRT group, and given
supplies and information regarding upcoming sessions.
- At the end of fMRI-2, you will be reminded of the quit date which you agreed upon
previously, and you will be given supplies and information regarding quitting.
- At the end of fMRI-3, you will be given reminders about upcoming sessions.
You will be instructed not to consume any alcohol on the night before each scanning session.
We will ask for a breath and saliva sample before each session to make sure you have
followed all directions about wearing the patch and smoking your usual brand or the
denicotinized cigarettes as instructed. If the test indicates that you have not followed
directions, you will be sent home (this will be considered a missed visit) and the visit
will be re-scheduled. If this occurs on 2 consecutive visits, your further participation in
the study will be terminated.
Follow-Up Sessions:
After completing all study visits, you will be asked to return for two follow-up sessions,
one at 6 months and one at 12 months from visit 1. At these follow-up sessions we will ask
for breath and saliva samples, and have you fill out paperwork regarding your mood and
current smoking status.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05176418 -
IV Pulsed-Nicotine as a Model of Smoking: The Effects of Dose and Delivery Rate
|
Early Phase 1 | |
Completed |
NCT04084210 -
Impact of Alternative Nicotine-Delivery Products on Combustible Cigarette Use
|
Phase 2 | |
Completed |
NCT04043728 -
Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study
|
N/A | |
Withdrawn |
NCT03707600 -
State and Trait Mediated Response to TMS in Substance Use Disorder
|
N/A | |
Recruiting |
NCT03999099 -
Targeting Orexin to Treat Nicotine Dependence
|
Phase 1 | |
Completed |
NCT03847155 -
Prevention of Nicotine Abstinence in Critically Ill Patients After Major Surgery
|
N/A | |
Completed |
NCT02840435 -
Study on Sit to Quit Phone Intervention
|
N/A | |
Completed |
NCT02139930 -
Project 2: Strategies for Reducing Nicotine Content in Cigarettes
|
N/A | |
Completed |
NCT01982110 -
A Mindfulness Based Application for Smoking Cessation
|
N/A | |
Completed |
NCT01926626 -
Evaluation of Moclobemide, a Reversible MAO-A Inhibitor, as an Adjunct to Nicotine Replacement Therapy in Female Smokers
|
Phase 2 | |
Completed |
NCT01569490 -
Striving to Quit: First Breath
|
N/A | |
Completed |
NCT01685996 -
Zonisamide Augmentation of Varenicline Treatment for Smoking Cessation
|
Phase 1/Phase 2 | |
Withdrawn |
NCT01569477 -
Striving to Quit-Wisconsin Tobacco Quit Line
|
N/A | |
Completed |
NCT01632189 -
The Effect of Varenicline on D2/D3 Receptor Binding in Smokers
|
N/A | |
Active, not recruiting |
NCT01182766 -
New Treatment for Alcohol and Nicotine Dependence
|
Phase 2/Phase 3 | |
Completed |
NCT00996034 -
Nicotine Vaccination and Nicotinic Receptor Occupancy
|
Phase 2 | |
Completed |
NCT01061528 -
Coping Skills Treatment for Smoking Cessation
|
N/A | |
Suspended |
NCT01636336 -
Effects of Progesterone on Smoked Nicotine Induced Changes in Hormones and Subjective Ratings of Stimulant Drug Effects
|
N/A | |
Completed |
NCT01943994 -
Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study
|
N/A | |
Withdrawn |
NCT01589081 -
Effects of Progesterone on IV Nicotine-Induced Changes in Hormones and Subjective Ratings of Stimulant Drug Effect
|
N/A |